A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies

• Male and female patients aged 18 years and older, inclusive;

• Patients must have a hematologic malignancy for which allogeneic hematopoietic peripheral blood cell transplantation is deemed clinically appropriate.

• Eligible diseases and stages include the following:

‣ Acute myeloid leukemia

‣ Acute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history of marrow involvement

‣ Myelodysplastic Syndrome

‣ Chronic myelogenous leukemia

• Availability of a suitable 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated mPB donor;

• mBP donor collection that meets protocol specifications;

• Adequate performance status, defined as Karnofsky score greater than or equal to 70%;

• For female patients of childbearing potential, all of the following criteria must be met:

‣ They are not pregnant (i.e., female patients must have a negative serum pregnancy test at screening);

⁃ They are not breastfeeding;

⁃ They do not plan to become pregnant during the study; and

⁃ They are using an effective method of contraception from screening to the end of the study, unless their sexual partner is surgically sterile.

• For male patients, agreement to use condoms with spermicide during sexual intercourse from screening to the end of study; and

• Willingness and ability to sign an IRB/IEC-approved ICF before performance of any study-specific procedures or tests and to comply with protocol visits, and study procedures.